Liver transplantation for HIV/hepatitis C virus co-infected patients

Hepatology Research

Volumn 44, Issue 1, 2014, Pages 17-21

  Takatsuki, Mitsuhisa ^a   Soyama, Akihiko ^a   Eguchi, Susumu ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Hepatitis C virus; HIV; Liver transplantation

Indexed keywords

ANTIRETROVIRUS AGENT; CALCINEURIN INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON; PROTEINASE INHIBITOR; RALTEGRAVIR; RAPAMYCIN; RIBAVIRIN; TELAPREVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MIXED INFECTION; NONHUMAN; PERIOPERATIVE PERIOD; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 84891835566     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12132     Document Type: Review

References (51)

1. Eguchi S, Soyama A, Hidaka M etal. Liver transplantation for patients with human immunodeficiency virus and hepatitis C virus coinfection with special reference to hemophiliac recipients in Japan. Surg Today 2011; 41: 1325-1331.
2. Weber R, Sabin CA, Friis-Moller N etal. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641.
3. Rosenthal E, Pialoux G, Bernard N etal. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14: 183-188.
4. Bica I, McGovern B, Dhar R etal. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497.
5. Darby SC, Ewart DW, Giangrande PL etal. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997; 350 (9089): 1425-1431.
6. Thio CL, Seaberg EC, Skolasky R etal. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360 (9349): 1921-1926.
7. de Vera ME, Dvorchik I, Tom K etal. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983-2993.
8. Schreibman I, Gaynor JJ, Jayaweera D etal. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007; 84: 697-705.
9. Duclos-Vallee JC, Feray C, Sebagh M etal. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-417.
10. Terrault NA, Roland ME, Schiano T etal., Solid Organ Transplantation in HIV: Multi-Site Study Investigators. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-726.
11. Miro JM, Montejo M, Castells L etal., Spanish OLT in HIV-Infected Patients Working Group Investigators. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant 2012; 12: 1866-1876.
12. Tsukada K, Sugawara Y, Kaneko J etal. Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: experience in a single center. Transplantation 2011; 91: 1261-1264.
13. Vispo E, Moreno A, Maida I etal. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24: 1171-1176.
14. Mendizabal M, Craviotto S, Chen T, Silva MO, Reddy KR. Noncirrhotic portal hypertension: another cause of liver disease in HIV patients. Ann Hepatol 2009; 8: 390-395.
15. Kovari H, Ledergerber B, Peter U etal., Swiss HIV Cohort Study. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49: 626-635.
16. Merchante N, Girón-González JA, González-Serrano M etal. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20: 49-57.
17. Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11: 1425-1430.
18. Baccarani U, Adani GL, Bragantini F etal. Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases. Transplant Proc 2011; 43: 1119-1122.
19. Rullier A, Trimoulet P, Neau D etal. Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients. Hum Pathol 2004; 35: 1088-1094.
20. Ragni MV, Moore CG, Soadwa K etal., HHH Study Group. Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia. Haemophilia 2011; 17: 103-111.
21. Resino S, Sánchez-Conde M, Berenguer J. Coinfection by human immunodeficiency virus and hepatitis C virus: noninvasive assessment and staging of fibrosis. Curr Opin Infect Dis 2012; 25: 564-569.
22. Merchante N, Rivero-Juárez A, Téllez F etal. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology 2012; 56: 228-238.
23. Sánchez-Conde M, Miralles P, Bellón JM etal. Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients. J Viral Hepat 2011; 18: 685-691.
24. Davison SP, Reisman NR, Pellegrino ED, Larson EE, Dermody M, Hutchison PJ. Perioperative guidelines for elective surgery in the human immunodeficiency virus-positive patient. Plast Reconstr Surg 2008; 121: 1831-1840.
25. Miro JM, Torre-Cisnero J, Moreno A etal. [GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]. Enferm Infecc Microbiol Clin 2005; 23: 353-362.
26. O'Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005). HIV Med 2005; 6 (Suppl 2): 149-153.
27. Xia XJ, Liu BC, Su JS etal. Preoperative CD4 count or CD4/CD8 ratio as a useful indicator for postoperative sepsis in HIV-infected patients undergoing abdominal operations. J Surg Res 2012; 174: e25-30.
28. Grossi PA. Update in HIV infection in organ transplantation. Curr Opin Organ Transplant 2012; 17: 586-593.
29. Joshi D, O'Grady J, Taylor C, Heaton N, Agarwal K. Liver transplantation in human immunodeficiency virus-positive patients. Liver Transpl 2011; 17: 881-890.
30. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 1112-1115.
31. García F, Plana M, Vidal C etal. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13: F79-86.
32. Neff GW, Bonham A, Tzakis AG etal. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239-247.
33. Castells L, Escartín A, Bilbao I etal. Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation 2007; 83: 354-358.
34. Frassetto LA, Browne M, Cheng A etal. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816-2820.
35. Armstrong MJ, Corbett C, Rowe IA, Taylor GP, Neuberger JM. HTLV-1 in solid-organ transplantation: current challenges and future management strategies. Transplantation 2012; 94: 1075-1084.
36. Tricot L, Teicher E, Peytavin G etal. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946-1952.
37. Sugawara Y, Tamura S, Yamashiki N etal. Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation. Transplant Proc 2012; 44: 791-793.
38. Tanaka T, Selzner N, Therapondos G, Renner EL, Lilly LB. Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. Transpl Int 2013; 26: 42-49.
39. Ueda Y, Takada Y, Marusawa H, Egawa H, Uemoto S, Chiba T. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation 2010; 90: 661-665.
40. Polard E, Camus C, Abault AY etal. Retransplantation for acute liver failure due to combined antiviral agents in an HIV-HCV coinfected liver transplant recipient. Transplantation 2005; 80: 1136-1138.
41. Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012; 142: 1314-1323.
42. Sugawara Y, Tamura S, Kokudo N. Liver transplantation in HCV/HIV positive patients. World J Gastrointest Surg 2011; 3: 21-28.
43. Lin YL, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. Cell surface CCR5 density determines the post-entry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci U S A 2002; 99: 15590-15595.
44. Weissman D, Dybul M, Daucher MB, Davey RT Jr, Walker RE, Kovacs JA. Interleukin-2 up-regulates expression of the human immunodeficiency virus fusion coreceptor CCR5 by CD4+ lymphocytes in vivo. J Infect Dis 2000; 181: 933-938.
45. Heredia A, Amoroso A, Davis C etal. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A 2003; 100: 10411-10416.
46. Di Benedetto F, Di Sandro S, De Ruvo N etal. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation 2010; 89: 733-738.
47. Chapuis AG, Paolo Rizzardi G, D'Agostino C etal. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000; 6: 762-768.
48. García F, Plana M, Arnedo M etal. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. J Acquir Immune Defic Syndr 2004; 36: 823-830.
49. Coull JJ, Turner D, Melby T, Betts MR, Lanier R, Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2001; 26: 423-434.
50. Marubashi S, Umeshita K, Asahara T etal. Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan. Clin Transplant 2012; 26: 857-867.
51. Klintmalm GB, Davis GL, Teperman L etal. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17: 1394-1403.